Switch theme
Sign up to access all valuation multiples
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
2010
1.3K+
LTM Revenue $599M
LTM EBITDA -$455M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ultragenyx has a last 12-month revenue (LTM) of $599M and a last 12-month EBITDA of -$455M.
In the most recent fiscal year, Ultragenyx achieved revenue of $560M and an EBITDA of -$469M.
Ultragenyx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ultragenyx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $599M | XXX | $560M | XXX | XXX | XXX |
| Gross Profit | $513M | XXX | $484M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$455M | XXX | -$469M | XXX | XXX | XXX |
| EBITDA Margin | -76% | XXX | -84% | XXX | XXX | XXX |
| EBIT | -$501M | XXX | -$536M | XXX | XXX | XXX |
| EBIT Margin | -84% | XXX | -96% | XXX | XXX | XXX |
| Net Profit | -$536M | XXX | -$569M | XXX | XXX | XXX |
| Net Margin | -89% | XXX | -102% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Ultragenyx's stock price is $34.
Ultragenyx has current market cap of $3.2B, and EV of $2.8B.
See Ultragenyx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $3.2B | XXX | XXX | XXX | XXX | $-5.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Ultragenyx has market cap of $3.2B and EV of $2.8B.
Ultragenyx's trades at 4.9x EV/Revenue multiple, and -5.9x EV/EBITDA.
Equity research analysts estimate Ultragenyx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ultragenyx has a P/E ratio of -6.0x.
See valuation multiples for Ultragenyx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | -6.1x | XXX | -5.9x | XXX | XXX | XXX |
| EV/EBIT | -5.5x | XXX | -5.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.0x | XXX | -5.7x | XXX | XXX | XXX |
| EV/FCF | 27.6x | XXX | -6.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUltragenyx's last 12 month revenue growth is 22%
Ultragenyx's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.8M for the same period.
Ultragenyx's rule of 40 is -97% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ultragenyx's rule of X is -21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ultragenyx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Margin | -76% | XXX | -84% | XXX | XXX | XXX |
| EBITDA Growth | -25% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -97% | XXX | -62% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 125% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 182% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ultragenyx acquired XXX companies to date.
Last acquisition by Ultragenyx was XXXXXXXX, XXXXX XXXXX XXXXXX . Ultragenyx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ultragenyx founded? | Ultragenyx was founded in 2010. |
| Where is Ultragenyx headquartered? | Ultragenyx is headquartered in United States of America. |
| How many employees does Ultragenyx have? | As of today, Ultragenyx has 1.3K+ employees. |
| Who is the CEO of Ultragenyx? | Ultragenyx's CEO is Dr. Emil D. Kakkis, M.D.,PhD. |
| Is Ultragenyx publicy listed? | Yes, Ultragenyx is a public company listed on NAS. |
| What is the stock symbol of Ultragenyx? | Ultragenyx trades under RARE ticker. |
| When did Ultragenyx go public? | Ultragenyx went public in 2014. |
| Who are competitors of Ultragenyx? | Similar companies to Ultragenyx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ultragenyx? | Ultragenyx's current market cap is $3.2B |
| What is the current revenue of Ultragenyx? | Ultragenyx's last 12 months revenue is $599M. |
| What is the current revenue growth of Ultragenyx? | Ultragenyx revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Ultragenyx? | Current revenue multiple of Ultragenyx is 4.6x. |
| Is Ultragenyx profitable? | Yes, Ultragenyx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ultragenyx? | Ultragenyx's last 12 months EBITDA is -$455M. |
| What is Ultragenyx's EBITDA margin? | Ultragenyx's last 12 months EBITDA margin is -76%. |
| What is the current EV/EBITDA multiple of Ultragenyx? | Current EBITDA multiple of Ultragenyx is -6.1x. |
| What is the current FCF of Ultragenyx? | Ultragenyx's last 12 months FCF is $100M. |
| What is Ultragenyx's FCF margin? | Ultragenyx's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Ultragenyx? | Current FCF multiple of Ultragenyx is 27.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
